FDA Approves Two Combination Therapies for HIV

The FDA recently approved two new combination therapies for the treatment of HIV infection in adults. Both therapies are pharmacoenhanced protease inhibitors (PIs). Evotaz by Bristol-Myers Squibb is a combination of 300 mg atazanavir (Reyataz, Bristol-Myers Squibb) and 150 mg cobicistat (a pharmacokinetic enhancer by Gilead Sciences), which should be used with other antiretroviral agents. Evotaz should be dosed once a day. Read more bit.ly/1yga8lR